Skip to content

A randomized double blind placebo-controlled clinical to access the validity and security of TiaoBuFeiShen capsule for chronic obstructive pulmonary disease in remission period(lung and kidney deficiency syndrome)

A randomized double blind placebo-controlled clinical to access the validity and security of TiaoBuFeiShen capsule for chronic obstructive pulmonary disease in remission period(lung and kidney deficiency syndrome)

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-13003947
Enrollment
Unknown
Registered
2013-12-04
Start date
2007-08-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic obstructive pulmonary disease

Interventions

The experimental group:TiaoBuFeiShen capsule

Sponsors

Second Affiliated Hospital of Tianjin University of TCM
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. meet the conventional medicine diagnosis standard of COPD; 2. meet the Chinese medicine diagnosis standard of lung and kidney deficiency syndrome; 3. the condition in the plateau,and belong to class II~III grade; 4. aged 40 to 70 years old; 5. did not attend other drug clinical research within a month; 6. participants voluntarily accept this kind of treatment, and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. merge the other diseases which causes short of breath or dyspnea; 2. allergic constitution (be allergic to two types of materials) or our agent composition, controlled drug allergies; 3. the gestation and preparation of pregnancy women, nursing mothers; 4. serum creatinine (Cr), urea nitrogen (BUN)exceed the upper limit of normal, cereal third transaminase (ALT) exceeds the upper limit of normal 1.5 times; 5. merge heart, brain, liver, kidney and hematopoietic system, severe primary disease and psychiatric patients.

Design outcomes

Primary

MeasureTime frame
blood routine examination;routine urine test;fecal examinations;liver functional tests;Kidney functional tests;ECG;Chest X-ray;Pulmonary function tests;Blood gas analysis;MMRC;SGRQ;6 minutes walking test;TCM symptom scores;

Countries

China

Contacts

Public ContactBaolin Wei

Second Affiliated Hospital Tianjin University of TCM

li_meifeng@126.com+86 15822455861

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026